US2020276185A1PendingUtilityA1
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Est. expiryJul 17, 2022(expired)· nominal 20-yr term from priority
A61K 31/4709A61K 45/06A61K 31/4748A61K 31/49A61K 2300/00A61K 31/485A61P 25/02
78
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Claims
exact text as granted — not AI-modified1 . A method for treating traumatic brain injury, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered comprises from about 20 mg/day to about 60 mg/day and wherein the amount of quinidine administered comprises from about 10 mg/day to about 30 mg/day with the proviso that the weight-to-weight ratio of dextromethorphan to quinidine is 1:0.75 or less of quinidine.
2 - 16 . (canceled)
17 . A method of treating pain associated with diabetic neuropathy, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered is 120 mg/day and wherein the amount of quinidine administered is 120 mg/day.
18 . A method of treating pain associated with diabetic neuropathy, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered is 90 mg/day and wherein the amount of quinidine administered is 90 mg/day.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.